AptarGroup Q2 Sales Top $1B but Margins Slip; Guides Q3 EPS $1.45-$1.53
ATR sits 29% above its 52-week low of $103.227.
Summary
AptarGroup posted record Q2 sales of $1.03B but saw margins compress, with operating income down 12% YoY. Q3 EPS guidance of $1.45-$1.53 was in line. A patent ruling due August 11 could affect the ophthalmic business.
Key Events · Earnings and Guidance · ATR
-
Record Sales, Lower Margins
Q2 net sales rose 6% to $1.03B, but operating income fell 12% to $126.7M as cost of sales increased to 64.4% of revenue from 62.0% a year ago, reflecting a shift toward lower-margin products and higher input costs.
-
Pharma Margin Compression
Pharma segment adjusted EBITDA margin declined to 33.6% from 35.4% YoY, driven by an anticipated reduction in high-margin emergency medicine sales, partially offset by growth in consumer healthcare and injectables.
-
Q3 Guidance In Line
Management guided Q3 adjusted EPS to $1.45-$1.53, assuming a 22.5%-24.5% tax rate and a 1.14 EUR/USD exchange rate. Full-year capex is expected to be $260M-$280M.
-
Share Repurchase Activity
Aptar repurchased 1.1M shares for $150M in H1 2026 under a $600M authorization announced in February 2026. $450M remains available for future buybacks.
Analysis · ATR · Industrial Applications And Services
Record quarterly sales of $1.03 billion topped consensus, yet operating income fell 12% year-over-year as cost pressures and a shift toward lower-margin products compressed profitability. The Pharma segment, typically the margin engine, saw its adjusted EBITDA margin drop to 33.6% from 35.4% a year ago, driven by an anticipated decline in high-margin emergency medicine sales. Q3 adjusted EPS guidance of $1.45-$1.53 came in roughly in line with expectations, but the margin trajectory warrants attention. On the capital allocation front, $150 million of stock was repurchased in the first half, with $450 million remaining under the authorization, signaling confidence in intrinsic value. A key legal overhang — the Nemera patent dispute — has a decision expected on August 11, 2026, which could impact the ophthalmic product line.
At the time of this filing, ATR was trading at $133.10 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $8.5B. The 52-week trading range was $103.23 to $158.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.